Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.33 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19104364 | 0.73 | HPGD (0.31) | GRM5GRM1 | |
| SCHEMBL16481654 | 0.72 | MAPT (0.46) | MAPTMKNK1MKNK2RETKDR | |
| SCHEMBL9008915 | 0.72 | SCN9A (0.39) | MAPTGRM5 | |
| SCHEMBL17151051 | 0.71 | MAPT (0.44) | MAPTMKNK1MKNK2JAK2RET | |
| SCHEMBL15633152 | 0.70 | GRM5 (0.34) | SLC16A3SLC16A1MCTS1GRM5GRM1 | |
| SCHEMBL4140061 | 0.70 | LMNA (0.48) | — | |
| SCHEMBL705177 | 0.70 | MAPT (0.56) | MAPTMKNK1MKNK2RETKDR | |
| SCHEMBL20187655 | 0.69 | NOTUM (0.39) | SYK | |
| SCHEMBL1456737 | 0.68 | HPGDS (0.51) | MAPT | |
| SCHEMBL26103853 | 0.68 | ADORA3 (0.38) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3656384-B1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3785714-A1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3125894-B1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3656384-A1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME CORP. (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3295942-B1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10189831-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10004740-B2 | Prodrugs of HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3295942-A1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME CORP. (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20170349585-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170349585-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-07 | — | — | US | disclosed |
| US-9469634-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469634-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160145255-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160145255-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
| WO-2015153304-A1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015153304-A1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-08 | — | — | WO | disclosed |
| EP-2903977-A1 | 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014058747-A1 | 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014058747-A1 | 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-04-17 | — | — | WO | disclosed |
| US-20140100231-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145255-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR2E, RTF1 | MAPT 1186/4885MKNK1 3425/4885MKNK2 3659/4885 |
| US-10004740-B2 | Prodrugs of HIV reverse transcriptase inhibitors | TYMP, RNGTT, REV1 | MAPT 1582/4885MKNK1 4005/4885MKNK2 4163/4885 |
| US-20140100231-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR2E, RTF1 | MAPT 1186/4885MKNK1 3425/4885MKNK2 3659/4885 |
| US-20170349585-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR2E, RTF1 | MAPT 1186/4885MKNK1 3425/4885MKNK2 3659/4885 |
| US-10189831-B2 | Non-nucleoside reverse transcriptase inhibitors | POLRMT, POLR2E, RTF1 | MAPT 1186/4885MKNK1 3425/4885MKNK2 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.